Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All CapsoVision, Inc filings on SEC EDGAR ↗
CapsoVision reported a net revenue of $10.0 million for the nine months ended September 30, 2026, a slight increase from $9.6 million in the prior year. However, the company experienced a net loss of $21.9 million during this period, driven by high research and development expenses as they pursue FDA clearances for new products like the CapsoCam Colon capsule and AI capabilities.
CapsoVision reported Q3 2026 revenue of $3.6 million and a gross margin of 49%, while highlighting the recent FDA clearance and launch of its AI Highlights tool. The company also completed enrollment for its second-generation CapsoCam Colon study and raised approximately $19.5 million in net proceeds through a registered direct offering and ATM program during the quarter.
Term
Q3 2026
“The FDA clearance and subsequent U.S. launch of AI Highlights marks an important step forward for CapsoVision. Our four-camera, 360-degree panoramic capsule already provides physicians with a differentiated view of the small bowel. By combining that imaging capability with AI-assisted review, we believe we can reduce reading time, improve detection accuracy compared with manual review, and give physicians an additional level of diagnostic confidence.”
Johnny Wang, President and Chief Executive Officer
“At the same time, completing enrollment in our colon clinical study brings us closer to our planned FDA submission by year end, which we believe represents a substantially larger market opportunity. With the support of our existing shareholders through our recent financing, we are focused on translating these milestones into broader adoption and long-term growth.”
Johnny Wang, President and Chief Executive Officer
CapsoVision received FDA clearance for AI Highlights, an AI-assisted reading tool for its CapsoCam Plus small bowel capsule endoscopy system. The tool is designed to reduce physician review time by automatically identifying and prioritizing images containing suspected abnormal lesions in patients with suspected small bowel bleeding.
CapsoVision Insider Eliyahou Et Al Harari Buys $10M of Stock
Eliyahou Et Al Harari bought 1,757,469 shares of CapsoVision, Inc at $5.69 a share, worth $10M in total on Sep 18, 2026. Shares held after the trade: 878,734.
CapsoVision Insider Ching Hang Shen Buys $5M of Stock
Ching Hang Shen bought 878,734 shares of CapsoVision, Inc at $5.69 a share, worth $5M in total on Sep 15, 2026. Shares held after the trade: 2,926,655 (+42.9%).
CapsoVision, Inc. entered into a securities purchase agreement for a registered direct offering of 3,163,444 shares of common stock at $5.69 per share. The offering raised approximately $18 million in gross proceeds from existing stockholders, including major investors Star One Global Capital Limited and Eliyahou Harari. The company intends to use the proceeds for general corporate purposes, including R&D and sales and marketing.
Value
$18M
Counterparty
Star One Global Capital Limited and Eliyahou Harari